- Molecular NameIrbesartan
- Synonymirbesartan
- Weight428.54
- Drugbank_IDDB01029
- ACS_NO138402-11-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.13
- pka6
- LogD (pH=7, predicted)0.63
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-3.84
- LogSw (predicted, AB/LogsW2.0)0.26
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors1
- No.of HBond Acceptors7
- No.of Rotatable Bonds7
- TPSA87.13
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn angiotensin II receptor antagonist used mainly for the treatment of hypertension.
- Absorption_value100.0
- Absorption (description)Irbesartan is almost completely absorbed after administration and steady state concentrations are reached within 3 to 4 days.
- Caco_2N/A
- Bioavailability70.0
- Protein binding90.0
- Volume of distribution (VD)0.72 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmEight metabolites have been identified and are formed by either glucuronidation or oxidation, primarily by the cytochrome P450 CYP2C9.
- Half life13 h
- ExcretionExcretion is mainly through faeces with less than 2% of an administered dose recovered unchanged in urine.
- Urinary Excretion2.2
- Clerance2.12 ml/min/kg
- ToxicityHypotension and tachycardia; bradycardia might also occur from overdose
- LD50 (rat)N/A
- LD50 (mouse)N/A